<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

A new line method; A direct test in spinal muscular atrophy screening for DBS

dc.contributor.authorKubar, Ayhan
dc.contributor.authorTemel, Sehime Gulsum
dc.contributor.authorBeken, Serdar
dc.contributor.authorOnder, Gizem
dc.contributor.authorHatirnaz, Ozden
dc.contributor.authorKorkmaz, Ayse
dc.contributor.authorAlanay, Yasemin
dc.contributor.authorOzbek, Ugur
dc.contributor.authorSag, Sebnem Ozemri
dc.contributor.authorErgoren, Mahmut Cerkez
dc.contributor.authorKubar, Elif
dc.contributor.authorSonmezalp, Candan Zeynep
dc.contributor.authorDogan, Ozlem
dc.date.accessioned2026-11-05T11:04:33Z
dc.date.issued2023
dc.description.abstractBackground: Nucleic acid-based assays provide an opportunity to screen for genetically encoded diseases like spinal muscular atrophy (SMA), before the onset of symptoms. Nowadays, such assays could be easily utilized as high-throughputs in SMA to detect a homozygous deletion of exon 7 of the survival motor neuron 1 gene (SMN1) that is responsible for >95% of SMA patients. Methods: We developed a new line method (NLM) as a direct real time PCR test procedure without nucleic acid extraction in dried blood spots (DBS) to screen for homozygous deletion of exon 7 of the SMN1 gene. Performance of this setup was evaluated on 580 DBS newborn samples and air dried 50 DBS from whole blood including 20 samples for homozygous deletion of the SMN1 gene detected earlier with MLPA. Results: We found all 580 newborn DBS samples as wild type. DBS prepared from 50 whole blood samples also including 20 affected people were correctly identified as homozygous deletions and 30 wild types of exon 7 of SMN1 as before with MLPA. When the MLPA method was taken as the gold standard, the sensitivity and specificity of the NLM test were found 100% for the detection of SMN1 exon 7 homozygous deletion. Conclusion: In the NLM, the total test duration has been reduced to less than 75 min without requiring any extra process such as DNA extraction step and sample plate preparation after the punching step. Thereby, newborn SMA screening with the NLM has gained an environmentally friendly feature with not requiring additional tedious steps.
dc.description.issue12
dc.description.pagese2270
dc.description.volume11
dc.identifier.doi10.1002/mgg3.2270
dc.identifier.issn2324-9269
dc.identifier.urihttps://doi.org/10.1002/mgg3.2270
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/11203
dc.identifier.wosWOS:001680626100001
dc.language.isoen
dc.publisherWILEY
dc.relation.hasversion10.1002/mgg3.2270
dc.relation.ispartofMOLECULAR GENETICS & GENOMIC MEDICINE
dc.subjectDBS
dc.subjectdirect test
dc.subjectnewborn screening
dc.subjectSMA
dc.subjectMANAGEMENT
dc.subjectDIAGNOSIS
dc.subjectSYSTEM
dc.subjectGenetics & Heredity
dc.titleA new line method; A direct test in spinal muscular atrophy screening for DBS
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.issue12
oaire.citation.volume11
person.identifier.orcid0000-0003-0740-3497
person.identifier.orcid0000-0003-0760-4088
person.identifier.ridW-8018-2018
person.identifier.ridAGN-3372-2022
person.identifier.ridJCO-5420-2023
person.identifier.ridAAG-8385-2021
person.identifier.ridD-8491-2018
person.identifier.ridAAH-8355-2021

Files

Collections